• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Cost-Effective Medication Access in Demodex Blepharitis Treatment


An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment.

This is a video synopsis/summary of an Insights involving Eric D. Donnenfeld, MD.

Demodex blepharitis is the leading reason that patients visit eye physicians, making up 40% to 50% of eye care professional appointments. Many patients are misdiagnosed and mistreated for aqueous-deficient dry eye with expensive immunomodulators instead of given the correct Demodex blepharitis diagnosis. Correct diagnosis and treatment with Xdemvy(lotilaner ophthalmic solution) significantly cuts costs.

Once diagnosed, Demodex blepharitis responds well to treatment. Lotilaner is a safe and effective 6-week, twice-daily course that improves ocular surface disease for at least 1 year, showing long-term stability for this previously unmanaged chronic condition.

It is important that patients understand Demodex pathogenesis because an eyelash mite infestation, in addition to clinical outcomes, usually motivates treatment adherence.

Video synopsis is AIgenerated and reviewed by AJMC® editorial staff.

Related Videos
Ronesh Sinha, MD
Yuqian Liu, PharmD
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
Related Content
© 2024 MJH Life Sciences
All rights reserved.